Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

Immune checkpoint receptors in autoimmunity

(2023) Kelly P Burke et al.   CURRENT OPINION IN IMMUNOLOGY

A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR

(2023) Runjie Song et al.   Molecular Cancer

Clinical application study on miR-98–5p as a prognostic biomarker in hepatocellular carcinoma

(2023) Peng-tian Ji et al.   Clinics and Research in Hepatology and Gastroenterology

Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion

(2023) Jakob G. Habib et al.   Frontiers in Immunology

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

(2023) Tomofumi Watanabe et al.   CANCER SCIENCE

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

(2023) Philippe Merle et al.   DIGESTIVE AND LIVER DISEASE

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment

(2023) Muhammad Joan Ailia et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Combination immunotherapy for hepatocellular carcinoma

(2023) Lorenza Rimassa et al.   JOURNAL OF HEPATOLOGY

Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment

(2023) Parviz Azimnasab-sorkhabi et al.   MOLECULAR BIOLOGY REPORTS

The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases

(2023) Sruthi Vijaya Retnakumar et al.   PHARMACOLOGY & THERAPEUTICS

Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities

(2023) Mona Meng Wang et al.   BRITISH JOURNAL OF CANCER

The cross-talk between LncRNAs and JAK-STAT signaling pathway in cancer

(2023) Ahmed Hjazi et al.   PATHOLOGY RESEARCH AND PRACTICE

Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

(2022) Chupeng Hu et al.   HEPATOLOGY

Eliminating METTL1 ‐mediated accumulation of PMN‐MDSCs prevents HCC recurrence after radiofrequency ablation

(2022) Xuezhen Zeng et al.   HEPATOLOGY

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

(2022) Karl L. Banta et al.   IMMUNITY

Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma

(2022) Mahsa Pourhamzeh et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Association of Gut Microbiome and Primary Liver Cancer: A Two‐sample Mendelian Randomization and Case‐control Study

(2022) Jun Ma et al.   LIVER INTERNATIONAL

Association between the side effect induced by COVID-19 vaccines and the immune regulatory gene polymorphism

(2022) Ding-Ping Chen et al.   Frontiers in Immunology

Designing Cancer Immunotherapies That Engage T Cells and NK Cells

(2022) Oleksandr Kyrysyuk et al.   Annual Review of Immunology

Anti-Claudin18.2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety

(2022) Yangyihua Zhou et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Targeted xCT‐mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti‐PD‐1/L1 Response

(2022) Bufu Tang et al.   Advanced Science

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2021) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

(2021) Marina K. Holz et al.   CELL

Overexpressed Tumor Suppressor Exosomal miR-15a-5p in Cancer Cells Inhibits PD1 Expression in CD8+T Cells and Suppresses the Hepatocellular Carcinoma Progression

(2021) Hong-Yu Zhang et al.   Frontiers in Oncology

TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

(2021) Zhouhong Ge et al.   Cellular and Molecular Gastroenterology and Hepatology

PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma

(2021) Mohammad Jalili-Nik et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

(2021) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of an Indomethacin Oral Spray on Pain Due to Oral Mucositis in Cancer Patients Treated With Radiotherapy and Chemotherapy: A Double-Blind, Randomized, Placebo-Controlled Trial (JORTC-PAL04)

(2021) Hiroka Nagaoka et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Emerging role of natural products in cancer immunotherapy

(2021) Songtao Dong et al.   Acta Pharmaceutica Sinica B

TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma

(2021) Shixiang Bao et al.   Frontiers in Oncology

miR-744-5p suppresses tumor proliferation and metastasis by targeting transforming growth factor-beta 1 (TGF-β1) in hepatocellular carcinoma (HCC)

(2021) Weifeng Huang et al.   Journal of Gastrointestinal Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

(2021) Thomas Yau et al.   LANCET ONCOLOGY

Immunotherapies for hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Clinical Oncology

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

(2021) Alan J. Korman et al.   NATURE REVIEWS DRUG DISCOVERY

CTLA-4: From mechanism to autoimmune therapy

(2020) Arezoo Hosseini et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes

(2020) Asmaa M. Zahran et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells

(2020) Yihe Yan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice

(2020) David Kung-Chun Chiu et al.   GASTROENTEROLOGY

Circulating CTLA-4 levels and CTLA4 polymorphisms associate with disease condition and progression and hepatocellular carcinoma patients' survival in chronic hepatitis B virus infection

(2020) Li Wang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

(2020) Xiao-Yong Huang et al.   Molecular Cancer

Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment

(2020) Federico Piñero et al.   Cells

Clinical Challenges of Immune Checkpoint Inhibitors

(2020) Maria de Miguel et al.   CANCER CELL

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma

(2020) Peng-Fei Zhang et al.   Molecular Cancer

Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines

(2020) Qian Qian et al.   Biomed Research International

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma

(2020) Wenjie Zhang et al.   Journal for ImmunoTherapy of Cancer

Dual angiogenesis and PD-1 blockade in hepatocellular carcinoma

(2020) Julien Calderaro   Hepatobiliary Surgery and Nutrition

TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells

(2020) Takuya Sekine et al.   Science Immunology

Golgi Membrane Protein 1 (GOLM1) Promotes Growth and Metastasis of Breast Cancer Cells via Regulating Matrix Metalloproteinase-13 (MMP13)

(2019) Rui Zhang et al.   MEDICAL SCIENCE MONITOR

Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy

(2019) Reena Varkey et al.   PLoS One

PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy

(2019) Arash Salmaninejad et al.   JOURNAL OF CELLULAR PHYSIOLOGY

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

(2019) Hui Li et al.   GASTROENTEROLOGY

Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cells

(2019) Yawei Zhao et al.   CARCINOGENESIS

Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma

(2019) Xiuqi Wu et al.   MOLECULAR THERAPY

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

Molecular and histological correlations in liver cancer

(2019) Julien Calderaro et al.   JOURNAL OF HEPATOLOGY

TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma

(2019) Xiaochen Wang et al.   JOURNAL OF HEPATOLOGY

Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk

(2019) Jing Yang et al.   MEDICINE

M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling

(2019) Zhaoyun Zong et al.   Frontiers in Immunology

Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC

(2019) Kohei Shigeta et al.   HEPATOLOGY

Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein

(2019) Junyang Wang et al.   NANO LETTERS

Racial disparities in alpha‐fetoprotein testing and alpha‐fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients

(2019) Guoyi Wu et al.   Cancer Medicine

Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas

(2019) Yi-Wen Hsiao et al.   Genes

Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma

(2019) Jingkai Xu et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

(2019) Shunli Peng et al.   Molecular Cancer

Association of CTLA‐4 , TNF alpha and IL 10 polymorphisms with susceptibility to hepatocellular carcinoma

(2019) Jia‐jia Wang et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma

(2019) Jiaqiang Ma et al.   Journal for ImmunoTherapy of Cancer

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

(2019) Gang Xiao et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy of Hepatocellular Carcinoma with Magnetic PD-1 Peptide-Imprinted Polymer Nanocomposite and Natural Killer Cells

(2019) Mei-Hwa Lee et al.   Biomolecules

Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma

(2018) Furong Liu et al.   BULLETIN DU CANCER

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma

(2018) Zachary J. Brown et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

(2018) Eric Wehrenberg-Klee et al.   CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

AMPK: Sensing Glucose as well as Cellular Energy Status

(2018) Sheng-Cai Lin et al.   Cell Metabolism

Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance

(2018) Marianne Ziol et al.   HEPATOLOGY

Immune checkpoint blockade for the treatment of human hepatocellular carcinoma

(2018) Naoshi Nishida et al.   HEPATOLOGY RESEARCH

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

(2018) Caroline Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis

(2018) Xiao-Lin Xu et al.   RADIOLOGY

Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma

(2018) Yusheng Cheng et al.   Cell Death & Disease

Predictive and preventive significance of AMPK activation on hepatocarcinogenesis in patients with liver cirrhosis

(2018) Xiaoli Yang et al.   Cell Death & Disease

Programmed Death Receptor 1 (PD1) Knockout and Human Telomerase Reverse Transcriptase (hTERT) Transduction Can Enhance Persistence and Antitumor Efficacy of Cytokine-Induced Killer Cells Against Hepatocellular Carcinoma

(2018) Kanghua Huang et al.   MEDICAL SCIENCE MONITOR

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

(2018) Jong-Ho Cha et al.   MOLECULAR CELL

Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy

(2018) Zeli Yin et al.   Molecular Cancer

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma

(2018) Xingliang Guo et al.   Frontiers in Pharmacology

Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1

(2017) Hui Li et al.   HEPATOLOGY

AASLD guidelines for the treatment of hepatocellular carcinoma

(2017) Julie K. Heimbach et al.   HEPATOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4

(2017) Xin Chen et al.   PATHOLOGY RESEARCH AND PRACTICE

Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages

(2017) W. K. Eddie Ip et al.   SCIENCE

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

(2017) Nicholas A. Manieri et al.   TRENDS IN IMMUNOLOGY

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

(2017) Maria Gato-Cañas et al.   Cell Reports

High-Density Lipoproteins: Nature’s Multifunctional Nanoparticles

(2016) Rui Kuai et al.   ACS Nano

Population attributable fractions of risk factors for hepatocellular carcinoma in the United States

(2016) Oxana V. Makarova-Rusher et al.   CANCER

GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis

(2016) Qing-Hai Ye et al.   CANCER CELL

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint

(2016) Jiang Chen et al.   Oncotarget

Long-term use of indomethacin leads to poor prognoses through promoting the expression of PD-1 and PD-L2 via TRIF/NF-κB pathway and JAK/STAT3 pathway to inhibit TNF-α and IFN-γ in hepatocellular carcinoma

(2015) Pingbo Xu et al.   EXPERIMENTAL CELL RESEARCH

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cellsex vivo

(2015) Alexander Pedroza-Gonzalez et al.   OncoImmunology

UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma

(2014) Raksha Mudbhary et al.   CANCER CELL

Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients

(2014) Johannes Landskron et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The PD-1/PD-Ls pathway and autoimmune diseases

(2014) Suya Dai et al.   CELLULAR IMMUNOLOGY

Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

(2014) Peter J. Murray et al.   IMMUNITY

Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis

(2014) Ole Helm et al.   INTERNATIONAL JOURNAL OF CANCER

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Insight into nanoparticle cellular uptake and intracellular targeting

(2014) Basit Yameen et al.   JOURNAL OF CONTROLLED RELEASE

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

A preventable cancer

(2014) Lucas Laursen   NATURE

Human CD14+CTLA-4+regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma

(2013) Yanmei Han et al.   HEPATOLOGY

Association between CTLA-4 60G/A and -1661A/G Polymorphisms and the Risk of Cancers: A Meta-Analysis

(2013) Qing Yan et al.   PLoS One

CTLA4-Ig Relieves Inflammation in Murine Models of Coxsackievirus B3-Induced Myocarditis

(2012) Bo Han et al.   CANADIAN JOURNAL OF CARDIOLOGY

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3

(2012) Jiajie Hou et al.   HEPATOLOGY

Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer

(2012) Alexander Pedroza-Gonzalez et al.   HEPATOLOGY

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

(2012) Hang Li et al.   HEPATOLOGY

Anti-oncogenic potential of the eIF4E-binding proteins

(2012) Y Martineau et al.   ONCOGENE

Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma

(2012) XIU-CHENG PAN et al.   Oncology Letters

Epidemiology and Surveillance of Hepatocellular Carcinoma

(2012) Do Young Kim et al.   Liver Cancer

Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C

(2011) Richard K Sterling et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Hepatocyte growth factor promotes an anti-inflammatory cytokine profile in human abdominal aortic aneurysm tissue

(2011) Yusuke Shintani et al.   ATHEROSCLEROSIS

Intercellular nanovesicle-mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth

(2011) Takayuki Kogure et al.   HEPATOLOGY

CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers—hepatocellular carcinoma and cervical cancer

(2010) Lingmin Hu et al.   HUMAN IMMUNOLOGY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

(2010) H.-T. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth

(2009) K. Iljin et al.   CLINICAL CANCER RESEARCH